Stock MAAT MAAT PHARMA
Add to a list
To use this feature you must be a member
Log inSign up

Financials MaaT Pharma

Equities

MAAT

FR0012634822

Biotechnology & Medical Research

Market Closed - Euronext Paris
Other stock markets
 08:05:14 2024-04-26 am EDT 		5-day change 1st Jan Change
9.06 EUR 0.00% Intraday chart for MaaT Pharma +3.90% +29.80%
Apr. 15 MaaT Pharma: positive data in graft-versus-host disease CF
Apr. 15 MaaT Pharma Presents Positive 18-Month Data for MaaT013 Showing a Clear Overall Survival Advantage in aGvHD from the Early Access Program at the 2024 EBMT Event CI

Valuation

Fiscal Period: December 2021 2022 2023 2024 2025 2026
Capitalization 1 131.9 79.15 80.99 105.1 - -
Enterprise Value (EV) 1 94.45 55.21 80.99 127.6 158.8 108.7
P/E ratio - - -4.11 x -3.55 x -3.52 x -4.03 x
Yield - - - - - -
Capitalization / Revenue 136 x - 36.4 x 26.3 x 23.9 x 10.7 x
EV / Revenue 97.2 x - 36.4 x 31.9 x 36.1 x 11.1 x
EV / EBITDA -11 x - -4.25 x -4.4 x -5.42 x -4.38 x
EV / FCF -11.6 x -4.16 x - -3.72 x -46.7 x -4.16 x
FCF Yield -8.65% -24% - -26.9% -2.14% -24%
Price to Book - - - -9.24 x -2.68 x -
Nbr of stocks (in thousands) 9,884 9,894 11,603 11,603 - -
Reference price 2 13.35 8.000 6.980 9.060 9.060 9.060
Announcement Date 4/14/22 3/31/23 3/28/24 - - -
1EUR in Million2EUR
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2020 2021 2022 2023 2024 2025 2026
Net sales 1 2.136 0.972 - 2.228 4 4.4 9.8
EBITDA 1 - -8.565 - -19.07 -29 -29.3 -24.8
EBIT 1 - - - -19.94 -29.5 -29.8 -25.9
Operating Margin - - - -895.11% -737.5% -677.27% -264.29%
Earnings before Tax (EBT) 1 - - - -19.72 -29 -32.9 -26.2
Net income 1 - - - -19.72 -29.6 -29.9 -26.2
Net margin - - - -884.96% -740% -679.55% -267.35%
EPS 2 -25.70 - - -1.700 -2.550 -2.575 -2.250
Free Cash Flow 1 - -8.167 -13.27 - -34.33 -3.4 -26.1
FCF margin - -840.23% - - -858.33% -77.27% -266.33%
FCF Conversion (EBITDA) - - - - - - -
FCF Conversion (Net income) - - - - - - -
Dividend per Share - - - - - - -
Announcement Date 10/4/21 4/14/22 3/31/23 3/28/24 - - -
1EUR in Million2EUR
Estimates

Balance Sheet Analysis

Fiscal Period: December 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 - - - - 22.5 53.7 3.54
Net Cash position 1 - 37.5 23.9 - - - -
Leverage (Debt/EBITDA) - - - - -0.7759 x -1.833 x -0.1426 x
Free Cash Flow 1 - -8.17 -13.3 - -34.3 -3.4 -26.1
ROE (net income / shareholders' equity) - - - - -487% - -
ROA (Net income/ Total Assets) - - - - - - -
Assets 1 - - - - - - -
Book Value Per Share 2 - - - - -0.9800 -3.380 -
Cash Flow per Share 2 - - -1.270 - -2.030 0.3600 -
Capex 1 - 0.24 0.66 - 1.67 1.47 1
Capex / Sales - 24.49% - - 41.67% 33.33% 10.2%
Announcement Date 10/4/21 4/14/22 3/31/23 3/28/24 - - -
1EUR in Million2EUR
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Ratings for MaaT Pharma

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
9.06 EUR
Average target price
15.5 EUR
Spread / Average Target
+71.08%
Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
MAAT PHARMA Stock MaaT Pharma
+29.80% 112M
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
-2.31% 103B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+0.56% 95.28B
ARGENX SE Stock argenx SE
+1.69% 22.15B
BIONTECH SE Stock BioNTech SE
-17.37% 21.02B
GENMAB A/S Stock Genmab A/S
-9.30% 18.15B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-41.01% 16.73B
BEIGENE, LTD. Stock BeiGene, Ltd.
-14.85% 16.05B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+3.21% 13.68B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+33.54% 12.17B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. MAAT Stock
  4. Financials MaaT Pharma